Suzanne Nicola Branford - Genetic Mutations

Author Information

Suzanne Nicola Branford is a prominent researcher affiliated with the Department of Genetics and Molecular Pathology at the Centre for Cancer Biology, SA Pathology in Adelaide, Australia. Her work primarily focuses on genetics, with a significant emphasis on chronic myeloid leukemia (CML) and related areas. Her research contributions have been influential in the field of cancer biology, particularly in understanding the genetic mechanisms and treatment responses in leukemia.

Research Contributions

Suzanne Nicola Branford has made substantial contributions to the field of genetics and cancer research, with a particular focus on chronic myeloid leukemia. Her recent work includes examining the genomic mechanisms influencing outcomes in CML, studying epigenetic modifier gene mutations associated with relapse risk, and investigating response-related predictors of survival and treatment-free remission. She has also explored advanced techniques such as droplet digital PCR for identifying patients with a high probability of achieving treatment-free remission and has contributed to standardizing RNA diagnostic practices.

Aliases

Suzanne Nicola Branford is also known by several aliases in academic publications, including S Branford, S. Branford, and Susan Branford. These variations are used across different research articles and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	18,317
H-index	57
Total Paper Count	300

Publications:

Commentary on Dominy et al., assessment of quantitative PCR for BCR::ABL1 Transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?

DOI: 10.1111/bjh.18046

Year: 2022

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique

DOI: 10.1111/bjh.18046

Year: 2022

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia

DOI: 10.3390/cancers14030620

Year: 2022

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

DOI: 10.1038/s41408-022-00667-9

Year: 2022

Response-Related Predictors of Survival and of Treatment-Free Remission in CML

DOI: 10.1007/978-3-030-71913-5_15

Year: 2021

Taming the gatekeeper: ponatinib dose holds the key.

DOI: 10.1182/blood.2021013284

Year: 2021

Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants

DOI: 10.1016/j.gim.2021.09.001

Year: 2021

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

DOI: 10.1038/s41467-021-23097-w

Year: 2021

Multiplex technologies for the assessment of minimal residual disease and low‐level mutation detection in leukaemia: mass spectrometry versus next‐generation sequencing

DOI: 10.1111/bjh.17623

Year: 2021

Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission

DOI: 10.1182/blood-2021-151966

Year: 2021

How do Genetic Mutations Affect Health?

What are the Ethical Considerations?

Who Should Consider Prenatal Screening and Genetic Counseling?

What is Populace Genomics?

How Does Phylogenetic Analysis Relate to Genetic Mutations?

Is Hydroxyurea Mutagenic?

What is a Deletion Mutation?

What Are the Common PARP Inhibitors?

Can Genetic Testing Help in Medication Management?

What is the Future of Pharmacogenomics?

Partnered Content Networks

Relevant Topics